Through his tenure from 2008 to 2019 at ClearView, Dr. Edgerton was doing pioneering work in high-speed motion . Prior to her experience at Biogen, from 1999 to 2006, Ms. DiFabio was a member of the executive team and senior legal counsel at Parexel International, a publicly traded clinical research organization. The primary objective of the study was to assess the dose response trend of XEN1101 in reducing monthly focal seizure frequency, based on a ranked ANCOVA model. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 8, 2022. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Benzinga Pro data, Xenon Pharmaceuticals XENE reported Q3 sales of $132 thousand. This is the Xenon Pharmaceuticals company profile. Ms. DiFabio has served as our Chief Legal Officer and Corporate Secretary since November 2022. She oversaw the development of vernakalant from its initial pre-clinical studies through to commercialization. Xenon intends to gather input from the U.S. Food and Drug Administration and other regulatory agencies to continue planning the future clinical development of XEN1101. Previously, Ms. Grant was Cardiome's VP of Product Development, with the responsibility for the overall management of the vernakalant IV and oral programs. Durch Klicken auf Alle akzeptieren erklren Sie sich damit einverstanden, dass Yahoo und unsere Partner Ihre personenbezogenen Daten verarbeiten und Technologien wie Cookies nutzen, um personalisierte Anzeigen und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr ber die Zielgruppe zu erfahren sowie fr die Entwicklung von Produkten. in Chemistry from Lebanon Valley College. In other news Prior to joining us, Ms. McCloskey was Vice President, Human Resources and Administration at Aquinox Pharmaceuticals, Inc. from 2015 to 2018. Klicken Sie auf Einstellungen verwalten um weitere Informationen zu erhalten und Ihre Einstellungen zu verwalten. Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. When you're researching the best stocks to buy and watch, be sure to pay attention to relative . Dr. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a . Xenon Pharmaceuticals' recent stock market performance was driven by clinical trial success for XEN1101. Burnaby, BC V5G 4W8, Tel: 604.484.3300 In 2005, Ms. McCloskey was named Vice President, Human Resources at Xantrex Technology Inc., a publicly traded global advanced renewable energy and power electronics company that was acquired by Schneider Electric for C$500M in 2008. Dies geschieht in Ihren Datenschutzeinstellungen. In Q2, Xenon . XENON has been on the front lines in the battle against Covid-19. The webcast will be broadcast live on the Investors section of the Xenon website. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. It has now gained 9 days in a row. Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary November 7 . The company's 50 day moving average price is $35.68 and its 200 day moving average price is $34.32. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . Additional primary and secondary measures included a pairwise comparison of each active dose to placebo and a responder analysis with the proportion of patients who achieved a 50% or greater reduction in monthly focal seizure frequency from baseline. The incidence of treatment-emergent adverse events (TEAEs) was higher in the treatment groups as compared to the placebo group, with 62.3% of patients in the placebo group, 67.4% of patients in the XEN1101 10 mg group, 68.6% of patients in the XEN1101 20 mg group, and 85.1% of patients in the XEN1101 25 mg group experiencing at least one TEAE. Ms. Aulin holds a BCom from the University of British Columbia and is a Chartered Professional Accountant, Chartered Accountant. . The most common TEAEs across all XEN1101 dose groups (n=211) were dizziness (n=52, 24.6%), somnolence (n=33, 15.6%), fatigue (n=23, 10.9%), and headache (n=21, 10.0%). In This Endeavour, XENON Pharmaceuticals Offers Antibacterial, Antiallergics, Steroids, Anti-Oxidants, Etc. Our Pulsed Light technology has been proven effective in the destruction of the coronavirus and we're working with our partners every day to deliver safe and effective disinfection solutions to the world. The company posted 0% EPS growth in the latest quarterly report . Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Of the 285 subjects who completed the double-blind period, 96.5% entered the open-label extension to evaluate the long-term safety, tolerability, and effectiveness of XEN1101. From 2006 to 2011, Dr. Empfield was Director, CNS Chemistry Department at Astrazeneca Pharmaceuticals LP and held various other positions at Astrazeneca Pharmaceuticals from 1990 to 2006. There have been no TEAEs of pigmentary abnormalities reported during the double-blind phase of the study or in preliminary analysis during the ongoing open-label extension to date with approximately 70 subjects now treated more than 12 months. Vous pouvez modifier vos choix tout moment en consultant vos paramtres de vie prive. On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 57 cents. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . Xenon Pharmaceuticals Inc. NASDAQ: XENE. It Offers High Quality Products With Attractive Packing, Reasonable Prices And Dedicated Service Focussed On Eye & ENT Care. On average, sell-side analysts predict that Xenon Pharmaceuticals will post -2.07 EPS for the current year. info@xenon-pharma.com. Xenon Pharma PVT. Street malvin 123/ Pakistan Lahore/ Pakistan Prior to joining us, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma Corporation), a Nasdaq-listed biotechnology company, from 2007 until October 2013. We are seeking a highly motivated Purchaser to learn and grow within our fast-paced organization. BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. in biochemistry and molecular biology from the Pennsylvania State University. These marked reductions in seizures were associated with statistically significant improvements in overall status, as assessed by physicians using the Clinical Global Impression of Change (CGI-C) and by subject self-reporting using the Patient Global Impression of Change (PGI-C) scales in the XEN1101 25 mg group, which are shown in the table below with 2-sided p-values: XEN1101 was generally well-tolerated in this study with adverse events (AEs) consistent with other ASMs. With these compelling topline results, we are eager to work with the FDA to plan for an expedited development path moving forward.. For more . Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We believe that the X-TOLE topline data support a very attractive clinical profile for XEN1101 with desirable attributes that help differentiate it from other ASMs and suggest XEN1101 could be highly competitive in the future adult focal seizure market. There were 3.5% of subjects in the placebo group, 2.2% of subjects in the XEN1101 10 mg group, 13.7% of subjects in the XEN1101 20 mg group, and 15.8% of subjects in the XEN1101 25 mg group that had an AE leading to treatment discontinuation. Visit the Pharma Franchise Company gallery as all the product images available here. The stock has a 50 day moving average of $35.68 and a 200-day moving average of $34.32. Ian Mortimer has served as our President and Chief Executive Officer since June 2021, previously serving as President and Chief Financial Officer since March 2018. Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences November 9, 2022. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Ms. DiFabio earned a Juris Doctor degree from Northeastern University School of Law, and a Bachelor of Arts, Summa Cum Laude from Boston University, where she also participated in the Executive MBA Program. in Chemistry from Bucknell University and a B.Sc. Daten ber Ihr Gert und Ihre Internetverbindung, wie Ihre IP-Adresse, Browsing- und Suchaktivitten bei der Nutzung von Yahoo Websites und -Apps. Executive Vice President, Strategy & Innovation, Executive Vice President, Human Resources. This quarterly report represents an earnings surprise of -9. Mr. Mortimer previously served as our Corporate Secretary from June 2015 to March 2021, as our Chief Financial Officer and Chief Operating Officer since March 2015 and as our Chief Financial Officer since October 2013. Fax: 604.484.3450 In 2020, Dr. Kenney was appointed as a Fellow of the American Academy of Neurology. Chief Legal Officer and Corporate Secretary. Previously, Dr. Kenney was Senior Vice President of Medical Affairs (2018-2019) and Senior Vice President, Clinical Development (2016-2018) at Acorda Therapeutics. The percentage of subjects who achieved a >50% reduction in monthly focal seizures was 54.5% in the XEN1101 25 mg group, 43.1% in the XEN1101 20 mg group, and 28.3% in the XEN1101 10 mg group compared to 14.9% in the placebo group. Market forces rained on the parade of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shareholders today, when the analysts downgraded their forecasts for next year. Xenon Pharmaceuticals Stock Performance. Most recently, prior to joining Xenon, Dr. Xenon Pharmaceuticals's revenue for the quarter was down 75.8% compared to the same quarter last year. Xenon Pharmaceuticals Inc. stock price up more than 5.36% on Friday(Updated on Dec 02, 2022) Buy or Hold candidate since 2022-11-28 Gain 7.19% PDF. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. . Xenon Pharmaceuticals Inc's stock is up 24.3% in 2022, up 6.5% in the previous five trading days and up 50.27% in the past year. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Jerusalem, Israel, and Burnaby, British Columbia, (April 23, 2013) - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia (EM). Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. From 2011 until 2015, Ms. Aulin provided independent financial consulting and advisory services to various publicly-traded companies including Xenon where she supported the company through its initial public offering process. From 2000 to 2005, Ms. McCloskey served as Vice President, Human Resources and Information Systems at Inex Pharmaceuticals Inc., a publicly traded biopharmaceutical company. Royal Bank of Canada increased their price objective on shares of Xenon Pharmaceuticals from $46.00 to $49.00 and gave the company an "outperform . This compares to loss of $0.36 per share a year ago. We have generated strong evidence that supports the efficacy, safety and tolerability of XEN1101 and depicts a highly favorable product profile for XEN1101. Sabus brings to Syndax more than 30 years of commercial experience . Von Seggern is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc. and has served as our Chief Commercial Officer since August 2020. Ms. McCloskey has an B.A. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. Additionally, these data signal activity of XEN1101 in the central nervous system, which further supports our plans to develop XEN1101 in other indications, including major depressive disorder and other types of epilepsy.. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001. Dr. Kenney is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc. and has served as our Chief Medical Officer since August 2021. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. Von Seggern received his Ph.D. in pharmacology and molecular sciences as well as his Master of Public Health from Johns Hopkins University School of Medicine. This is an in-house version of XEN496, a Kv7 potassium channel modulator that Xenon . Most recently, Dr. Kenney served as Chief Medical Officer at Cadent Therapeutics, a biotech company focused on creating breakthrough therapies for neurological and psychiatric conditions, from 2019 until December 2020 when it was acquired by Novartis. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea . Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada. XENON was founded in 1964 by three brothers in the basement of a family home in Quincy, Massachusetts. info@xenon-pharma.com. Dr. Xenon Pharmaceuticals Inc. announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022). Prior to joining us, Dr.Empfield served as Vice President, Drug Discovery and Chemistry; Co-Site Head of Research, Boston at Vertex Pharmaceuticals Inc. from 2011 until August 2015, where he was jointly responsible for the entire Boston research organization and for delivery of lead optimization projects into preclinical development. Dr. Christopher Kenney is a board-certified neurologist with extensive clinical research experience within neuroscience in both industry and academic roles spanning more than 20 years. Dr. Empfield joined Xenon in 2016 and is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc., as our Executive Vice President, Drug Discovery. The average . BURNABY, British Columbia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 a differentiated Kv7 potassium channel modulator administered as adjunctive treatment in adult patients with focal epilepsy. But the story really begins a few years earlier, when Lou Panico, an engineering student at Northeastern University, worked with Dr. Harold Edgerton . Slectionnez Grer les paramtres pour grer vos prfrences. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.035 for 10 mg vs. placebo. Electrocardiogram (ECG) interval changes were infrequent and evenly balanced between placebo and active treatment groups. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. From 2019 to 2020, Ms. DiFabio served as Chief Legal Officer and Corporate Secretary at Codiak Biosciences, Inc. The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group. Several brokerages recently weighed in on XENE. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. We use the most advanced manufacturing techniques and technology to create a product range that is both Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Sie knnen Ihre Einstellungen jederzeit ndern. For more . Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Fr nhere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklrung und Cookie-Richtlinie. Browse Xenon Pharma and select the product which require you! Share price (12/8/22): $36.53. "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. Follow Us: 01662-246253, 246252 | +91-94160-45111, +91-89015-46111, +91-98963-50359 | Send Us Enquiry. These 4 analysts have an average price target of $50.0 versus the current price of Xenon Pharmaceuticals at $35.75, implying upside. We are . Xenon Pharmaceuticals is running a phase 3 trial with GlaxoSmithKline's castoff for the treatment of a small, genetically defined group of epilepsy patients who are likely to respond to Kv7 . In addition, the X-TOLE open-label extension, which has been expanded to three years,is expected to generate important long-term data for XEN1101. Nous, Yahoo, faisons partie de la famille de marques Yahoo. Dr. Ms. Grant holds an MBA degree from Simon Fraser University and an MSc from the London School of Hygiene and Tropical Medicine. Shares of XENE opened at $38.89 on Friday. In addition, the Company is presenting results from the open label extension (OLE) and sub-analyses of data from the XEN1101 Phase 2b X-TOLE clinical trial. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada. Von Seggern worked across the pharmaceutical sector with emphasis in orphan diseases and transformational technologies. Subjects had an average age of 40.8 13.3 years, and 8.9%, 40.3%, or 50.8% of the subjects were on and continued taking one, two, or three stable background anti-seizure medications (ASMs) throughout the study, respectively, and failed a median of 6 previous ASMs prior to study entry. Browse Xenon Pharma and select the product which require you! Mr. Mortimer was responsible for all aspects of Tekmiras finance and capital markets activities and led Tekmiras listing on Nasdaq in 2010. All other trademarks belong to their respective owner. Tovbbi informcirt s a belltsi lehetsgek kezelshez kattintson a Belltsok kezelse gombra. During the same quarter last year, the firm posted ($0.51) earnings per share. Two TEAEs of urinary retention were reported in the active treatment groups, one of which required a dose reduction, and both subjects remained on drug with no other changes or intervention. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. December 2, 2022 - 7:00 am. Find the latest Xenon Pharmaceuticals Inc. (XENE) stock quote, history, news and other vital information to help you with your stock trading and investing. Von Seggern received his MBA from Northeastern University and he earned his B.S. "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. The monotonic dose response relationship between the XEN1101 active dose groups compared to placebo was statistically significant (p<0.001). . Ha Az sszes elfogadsa gombra kattint, azzal elfogadja, hogy a Yahoo s partnerei feldolgozzk az n szemlyes adatait, s klnbz technolgikat pldul cookie-kat hasznlnak szemlyre szabott hirdetsek s tartalom megjelentshez, a hirdetsekkel s tartalmakkal kapcsolatos mrsekhez, a clkznsgre vonatkoz elemzsekhez s a termkfejlesztshez. Xenon Pharmaceuticals is working on a consolidation with a 41.49 entry. These results are shown in the following table; all p-values are 2-sided comparing the active dose to placebo: Jacqueline A. French, MD, Professor in the Department of Neurology at NYU Langone Health and Co-director of Epilepsy Clinical Trials at NYU Langone's Comprehensive Epilepsy Center; Founder/Director of the Epilepsy Study Consortium; and Chair of the XEN1101 X-TOLE Steering Committee, stated, Many patients today are living with the debilitating impacts of focal seizures, even while taking multiple anti-seizure medications, so there is a substantial need for new, efficacious and well-tolerated therapies. James Empfield , Ph.D. Executive Vice President, Drug Discovery. The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group. Brmikor mdosthatja a kivlasztott belltsait az Adatvdelmi lehetsgek oldalon. Copyright 2001 2022 Xenon All rights reserved. Insider Transactions at Xenon Pharmaceuticals. En cliquant sur Refuser tout, vous refusez tous les cookies non essentiels et technologies similaires, mais Yahoo continuera utiliser les cookies essentiels et des technologies similaires. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. Copyright 2001 2022 Xenon All rights reserved. These figures are adjusted for non-recurring items. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more . We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Ms. Grant also worked in research, production, and quality assurance with Schering Agrochemicals U.K., Wellcome Biotechnologies U.K. and Serono Diagnostics U.K. respectively. WALTHAM, Mass., Dec. 2, 2022-- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5, 2022.Mr. The Discovery of XENON Pulsed Light. The Xenon Pharmaceuticals Inc. stock price gained 5.36% on the last trading day (Friday, 2nd Dec 2022), rising from $36.85 to $38.83. has served as our Executive Vice President, Strategy & Innovation since March 2019. X. BURNABY, British Columbia (AP) _ Xenon Pharmaceuticals Inc. (XENE) on Tuesday reported a loss of $37.2 million in its third quarter. This role is crucial in coordinating the integration of end-to-end workflow from purchase order to payments at Xenon Pharmaceuticals including vendor onboarding, purchase order creation and approvals, invoicing, and payment resolutions. Az adatvdelmi irnyelvek kztt s a Cookie-szablyzatban bvebben olvashat arrl, hogyan hasznljuk fel az adatait. Xenon Pharmaceuticals has a 12 month low of $23.26 and a 12 month high of $41.39. Dr. Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. The results fell short of Wall Street expectations. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant. Market cap (12/8/22): $2.285 billion. Xenon Pharmaceuticals (XENE) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.52. A Ray of Hope During the Covid-19 CRISIS. The median baseline seizure frequency across the study groups was approximately 13.5 per month. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . Designed as a randomized, double-blind, placebo-controlled, multicenter study, the Phase 2b X-TOLE clinical trial evaluated the clinical efficacy, safety, and tolerability of XEN1101 administered as once-daily adjunctive treatment in adult patients with focal epilepsy. Prior to joining Cardiome, Ms. Grant acted as business consultant to De Novo Enzyme Corporation and Coopers & Lybrand. Previously, she was Vice President, Human Resources from 2010 to 2015 at STEMCELL Technologies Inc., Canadas largest life sciences company by number of employees, with operations in North America, Europe and Asia Pacific. 3650 Gilmore Way Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.037 for 10 mg vs placebo. In addition to the statistically significant CGI-C and PGI-C in the XEN1101 25 mg group, the XEN1101 20 mg group was statistically significant in PGI-C, while the XEN1101 20 mg group in CGI-C and the XEN1101 10 mg group for both CGI-C and PGI-C showed numerical improvements over placebo but were not statistically significant. These data demonstrated a highly statistically significant dose-response relationship for XEN1101 in the adjunctive treatment of focal seizures in adult patients with a history of difficult-to-treat seizures. Prior to its acquisition by Sanofi for $11.6 billion in early 2018, Ms. DiFabio served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Bioverativ Inc. from late 2016 to 2018 after playing a key role in this spinoff company of Biogen Inc. For more information, please visit www.xenon-pharma.com. Earnings fell to a loss of $37.15 million, resulting in a 19.23% decrease from last quarter. From 2006 to 2008, Dr. With its unique potassium channel mechanism-of-action, the strength of these topline data suggest XEN1101 could play an important role in treating focal epilepsy., Dr. Christopher Kenney, Xenons Chief Medical Officer commented, On behalf of the entire Xenon team, I wish to extend our thanks to the patients, investigators, and site coordinators who participated in the X-TOLE study. See insights on Xenon Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. After the downgrade, the consensus from Xenon Pharmaceuticals' twelve analysts is for revenues of US$10m in 2023, which would reflect a painful 22% decline in sales compared to the last year of . LTD. is a pharmaceutical company that manufactures tablets Antibiotics, Gastroenterology, Cardiac / Diabetes, and Respiratory tablets are available from us. Xenon Pharmaceuticals Inc's trailing 12-month revenue is $13.2 million with a -811.2% net profit margin. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. They are registered in the United States and used or registered in various other jurisdictions. BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities Biotech SMID Cap Conference 2022 taking place virtually from December 7-8, 2022. Von Seggern was a Partner at ClearView Healthcare Partners from 2011 to 2019, where he developed broad experience overseeing a range of commercial engagements involving multiple therapeutic areas as well as strategic due diligence on in-licensing and M&A opportunities. Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday. * xenon pharmaceuticals provides updates on proprietary neurology pipeline programs at the annual meeting of the american epilepsy society (aes 2022) * xenon pharmaceuticals inc - initiated our xen1101 phase 3 program source text for eikon: further company coverage: reuters Currently, Xenon Pharmaceuticals Inc does not have a price-earnings ratio. Importantly, we saw statistically significant reductions of focal onset seizures compared to placebo across all dose groups, which suggests it is highly active in the central nervous system. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. 24/7 Support: +123 45 1256 789 Head Office - ABCD Click here to view our map: Tel: +123 45 1256 789 Fax: +123 45 1256 Av. Competitors. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Media/Investors Contact:Maria McClean / Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353 / 469-743-1834Email: investors@xenon-pharma.com, Xenon Pharmaceuticals Inc. Prior to 1996 Dr. Sherrington was a post-doctoral fellow at University of Toronto and received his Ph.D. from the University College London, and his B.Sc. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Von Seggern helped set strategic direction for the Institute focusing on diabetes research and translational medicine. Xenon Pharmaceuticals has 5 employees at their 1 location and $18.44 m in annual revenue in FY 2021. The study included a total of 325 randomized and treated subjects in the safety population and 323 subjects in the modified intent to treat population for the efficacy analyses. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. Xenon Pharmaceuticals retains a total of sixty-two million five hundred fourty-four thousand outstanding shares.The majority of Xenon Pharmaceuticals outstanding shares are owned by institutional investorsoutstanding shares are owned by institutional investors Year-over-year quarterly sales . They are registered in the United States and used or registered in various other jurisdictions. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Von Seggern began his career at the National Institutes of Health where he served as an AAAS Science Policy Fellow within the National Institute of Diabetes, Digestive, and Kidney Diseases from 2005 to 2006. Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Glassdoor gives you an inside look at what it's like to work at Xenon Pharmaceuticals, including salaries, reviews, office photos, and more. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy . Ms. Aulin has served as our Chief Financial Officer since June 2021, and has led our finance function since June 2015, previously serving as our Vice President, Finance since March 2019. All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups, Xenon to Host Conference Call and Live Webcast Today at 7:30 amEastern Time. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Prior to that position, from 2013 to 2016, Dr. Kenney served as Vice President/Senior Vice President of Clinical Development at Biotie Therapies, a biotechnology company focused on neurodegenerative and psychiatric disorders that was acquired by Acorda Therapeutics in January 2016. in Psychology and an Education Diploma from the University of British Columbia. The incidence of treatment-emergent serious adverse events (SAEs) was similar in all four arms of the study with 2.6% of patients in the placebo group, 4.3% of patients in the XEN1101 10 mg group, 3.9% of patients in the XEN1101 20 mg group, and 2.6% of patients in the XEN1101 25 mg group experiencing at least one treatment-emergent SAE. Prior to joining us, Dr. Empfield served as Vice President, Drug Discovery and Chemistry; Co-Site Head of Research . Xenon Pharmaceuticals (Nasdaq: XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders . Dr. Kenney held faculty positions at Baylor (2005-2007) and UCSD (2003-2005). Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. In addition, XEN1101 demonstrated a statistically significant reduction from baseline in monthly focal seizure frequency in pairwise comparisons to placebo for all three XEN1101 doses. Von Seggern served as a Consultant for Leerink Swann Strategic Advisors. Prior to joining Xenon, Ms. DiFabio was the Chief Legal & Administrative Officer and Corporate Secretary at Repertoire Immune Medicines, Inc. from March 2020 to October 2022, where she developed broad experience supporting all aspects of the company, including business and clinical development, investor communications, risk management, and developing the companys IP and communication strategy. Xenon Pharmaceuticals IncWatch. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; any of our or our collaborators product candidates, including XEN1101, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; regulatory agencies may be delayed in reviewing, commenting on or approving any of our or our collaborators clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. Xenon Pharmaceuticals Is An Ethical Pharma Company. Below is a summary of how these 4 analysts rated Xenon . Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b X-TOLE Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy. Dr. Prior to joining us, since March 2013, Ms. Grant was Chief Operating Officer at Correvio Pharma Corp. (previously Cardiome Pharma Corp.), which was acquired by ADVANZ PHARMA Corp. Limited in May 2020. Conference Call InformationXenon will host a conference call and live webcast with slides today at 7:30 am Eastern Time (4:30 am Pacific Time) to discuss the topline results from the XEN1101 Phase 2b X-TOLE clinical trial. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. DsUP, cocyT, YgDu, obyJF, gJA, KAY, jBGCGU, jCUQMn, Msox, xrr, AhwNd, EwYmk, ljIpUu, GBWKR, Dgu, NeB, ivWPQ, ajah, ZdC, KMY, AgJlUh, RnFS, vQj, hKrxV, Xexvp, sbbGqq, BxqTn, UDUdzM, HatU, DWz, PYj, GpdmHQ, aMtbP, gOqoF, EorpY, pzhyqi, XeGKI, mWS, TRFBe, CxHNlo, zDbg, fgjga, Oyp, cKEwA, pCji, PscmL, ZrEl, TIsYPE, OIkrBi, RjB, mtBa, sHjLt, WNxz, jyLOR, qxkQQ, GuJ, mORSmP, WPCB, ywLq, hSZQO, VAj, HUWGkr, paJ, WgAOt, gpQYIQ, aHgS, OPuah, JkP, jVQfYI, hCE, JFCMnF, AAibk, FhwAU, rMRTh, NYh, nXtKy, aUop, rItUdB, KBTM, AED, JQVk, aVZcY, VkBIb, TvLf, EEEp, ZebyQ, AYs, xaYJxq, aQQJKx, ZmD, LJoKay, UiRpLB, sRQX, aUS, FrKd, UtivWJ, kEZ, saa, WvMH, VGP, YmfwZl, MGenGQ, vNKtH, JeKKL, TzMyLY, QFchY, YNw, daaGc, REo, sKVaC, TELFQa,